LAVA Therapeutics Future Growth
Future criteria checks 2/6
LAVA Therapeutics's earnings are forecast to decline at 8.7% per annum while its annual revenue is expected to grow at 52.4% per year. EPS is expected to grow by 6.2% per annum.
Key information
-8.7%
Earnings growth rate
6.2%
EPS growth rate
| Biotechs earnings growth | 24.0% |
| Revenue growth rate | 52.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 22 Mar 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -78 | -40 | N/A | 4 |
| 12/31/2025 | N/A | -63 | -32 | N/A | 4 |
| 12/31/2024 | 3 | -42 | -29 | N/A | 4 |
| 12/31/2023 | 7 | -42 | -40 | -39 | N/A |
| 9/30/2023 | 9 | -50 | 6 | 7 | N/A |
| 6/30/2023 | 24 | -41 | -1 | 0 | N/A |
| 3/31/2023 | 20 | -36 | 3 | 3 | N/A |
| 12/31/2022 | 19 | -32 | 3 | 4 | N/A |
| 9/30/2022 | 18 | -25 | -40 | -39 | N/A |
| 6/30/2022 | 5 | -33 | -34 | -33 | N/A |
| 3/31/2022 | 5 | -32 | -33 | -32 | N/A |
| 12/31/2021 | 5 | -42 | -29 | -29 | N/A |
| 9/30/2021 | 6 | -37 | -29 | -28 | N/A |
| 6/30/2021 | 5 | -34 | -25 | -24 | N/A |
| 3/31/2021 | 5 | -31 | -12 | -11 | N/A |
| 12/31/2020 | 4 | -16 | -10 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LVTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LVTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LVTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LVTX's revenue (52.4% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: LVTX's revenue (52.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LVTX's Return on Equity is forecast to be high in 3 years time